Literature DB >> 16895973

Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity.

A R Fraser1, G Cook, I M Franklin, J G Templeton, M Campbell, T L Holyoake, J D M Campbell.   

Abstract

Production of the anti-inflammatory cytokine IL-10 by monocytes has been implicated as a probable negative regulator of graft-versus-host disease (GvHD) in patients undergoing allogeneic stem cell transplants (SCT). Monocytes from G-CSF-mobilized peripheral blood stem cell (gmPBSC) collections have been reported to produce more IL-10 than unmobilized monocytes in response to proinflammatory factors such as LPS. Why this should occur is unclear. In this study, monocyte phenotype and IL-10 localization and release were investigated in PB mononuclear cells (MNC) from 27 healthy donors mobilized for allogeneic SCT and from 13 patients with hematological malignancies mobilized for autologous SCT. All isolates contained elevated total percentages of monocytes in comparison with unmobilized PB, a high proportion of which displayed an immature phenotype. Stimulation of gmPB MNC with an inflammatory stimulus [fixed Staphylococcus aureus cells (SAC)] induced rapid up-regulation of CD14, indicating conversion to mature status. Localization studies indicated that IL-10 was predominantly present, bound on the surface of CD64(+)/CD14(low/neg) immature monocytes. Inflammatory stimuli (LPS, polyinosinic:polycytidylic acid, or SAC) induced release of variable quantities of IL-10 from the cell surface. MNC, separated into surface IL-10-positive or -negative fractions, differed in their ability to stimulate alloreactivity in MLR, and IL-10(+) MNC induced significantly lower levels of proliferation than IL-10(-) MNC. Thus, the subset of immature monocytes carrying surface-bound IL-10 in gmPB has the potential to modulate alloreactivity and GvHD after allogeneic SCT through cell-to-cell contact and released IL-10.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895973     DOI: 10.1189/jlb.0605297

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  10 in total

1.  Bone-marrow-derived side population cells for myocardial regeneration.

Authors:  Hesham A Sadek; Cindy M Martin; Shuaib S Latif; Mary G Garry; Daniel J Garry
Journal:  J Cardiovasc Transl Res       Date:  2009-03-19       Impact factor: 4.132

Review 2.  Effects and safety of granulocyte colony-stimulating factor in healthy volunteers.

Authors:  Paolo Anderlini
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 3.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

4.  Th2 Cytokines IL-4, IL-13, and IL-10 Promote Differentiation of Pro-Lymphatic Progenitors Derived from Bone Marrow Myeloid Precursors.

Authors:  Maria Espinosa Gonzalez; Lisa Volk-Draper; Nihit Bhattarai; Andrew Wilber; Sophia Ran
Journal:  Stem Cells Dev       Date:  2022-05-23       Impact factor: 4.390

5.  Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting protective NK cell, macrophage and T cell responses.

Authors:  Katherine T Morris; Eliseo F Castillo; Anita L Ray; Lea L Weston; Robert A Nofchissey; Joshua A Hanson; Von G Samedi; Irina V Pinchuk; Laurie G Hudson; Ellen J Beswick
Journal:  Oncotarget       Date:  2015-09-08

6.  Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML.

Authors:  Ulla Impola; Antti Larjo; Urpu Salmenniemi; Mervi Putkonen; Maija Itälä-Remes; Jukka Partanen
Journal:  Front Immunol       Date:  2016-11-21       Impact factor: 7.561

Review 7.  Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection.

Authors:  Bao-Guo Xiao; Chuan-Zhen Lu; Hans Link
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

8.  Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes.

Authors:  Samantha K Dunmire; Oludare A Odumade; Jean L Porter; Juan Reyes-Genere; David O Schmeling; Hatice Bilgic; Danhua Fan; Emily C Baechler; Henry H Balfour; Kristin A Hogquist
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

9.  G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer.

Authors:  Maija Hollmén; Sinem Karaman; Simon Schwager; Angela Lisibach; Ailsa J Christiansen; Mikael Maksimow; Zsuzsanna Varga; Sirpa Jalkanen; Michael Detmar
Journal:  Oncoimmunology       Date:  2015-11-24       Impact factor: 8.110

10.  Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.

Authors:  Guro Kristin Melve; Elisabeth Ersvaer; Geir Egil Eide; Einar K Kristoffersen; Øystein Bruserud
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.